Belite Bio Inc Adr (BLTE)

04:19 AM

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

04:19 AM

Oct 09, 2025

Belite Bio (NASDAQ:BLTE) Given Sell (D-) Rating at Weiss Ratings - MarketBeat

Oct 09, 2025

Oct 03, 2025

What MACD signals say about Belite Bio Inc Depositary Receipt2025 Top Gainers & Real-Time Market Trend Scan - newser.com

Oct 03, 2025

Oct 03, 2025

GAMMA Investing LLC Trims Stock Holdings in Belite Bio, Inc. Sponsored ADR $BLTE - Defense World

Oct 03, 2025

Oct 02, 2025

3 Lesser-Known Healthcare Names With Major Upside in Store - Investing.com

Oct 02, 2025

Sep 30, 2025

Volume spikes in Belite Bio Inc Depositary Receipt stock – what they mean2025 Support & Resistance & Reliable Breakout Forecasts - newser.com

Sep 30, 2025

Sep 24, 2025

Juvenile Macular Degeneration Pipeline 2025: Innovative Clinical Developments by 80+ Global Leaders – DelveInsight | Highlighting Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen - Barchart.com

Sep 24, 2025

Sep 24, 2025

Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeHere's Why - MarketBeat

Sep 24, 2025

Sep 23, 2025

Belite Bio (NASDAQ:BLTE) Upgraded at Wall Street Zen - MarketBeat

Sep 23, 2025

Sep 22, 2025

Belite Bio (NASDAQ:BLTE) Upgraded by Zacks Research to "Hold" Rating - MarketBeat

Sep 22, 2025

Sep 22, 2025

Analysts Set Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) PT at $96.00 - MarketBeat

Sep 22, 2025

Sep 21, 2025

HC Wainwright Has Positive Outlook of Belite Bio Q3 Earnings - MarketBeat

Sep 21, 2025

Sep 21, 2025

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives $96.00 Average Target Price from Analysts - Defense World

Sep 21, 2025

Sep 19, 2025

HC Wainwright Has Lowered Expectations for Belite Bio (NASDAQ:BLTE) Stock Price - MarketBeat

Sep 19, 2025

Sep 18, 2025

Oculis Holding (OCS) Gets a Buy from H.C. Wainwright - The Globe and Mail

Sep 18, 2025

Sep 18, 2025

What is HC Wainwright’s Estimate for Belite Bio Q3 Earnings? - Defense World

Sep 18, 2025

Sep 16, 2025

Belite Bio concludes phase 3 DRAGON study for Stargardt disease - Modern Retina

Sep 16, 2025

Sep 16, 2025

VolitionRX (VNRX) Gets a Hold from Benchmark Co. - The Globe and Mail

Sep 16, 2025

Sep 16, 2025

Belite Bio (NASDAQ:BLTE) Given New $98.00 Price Target at HC Wainwright - Defense World

Sep 16, 2025

Sep 15, 2025

Belite Bio Shares Climb Amid Clinical Progress - TipRanks

Sep 15, 2025

Sep 15, 2025

Belite Bio stock price target lowered to $98 at H.C. Wainwright on share count - Investing.com

Sep 15, 2025

Sep 14, 2025

Promising Outlook for Belite Bio, Inc. Amidst Phase 3 Success and Strong Financial Position - TipRanks

Sep 14, 2025

Sep 13, 2025

Belite Bio (NASDAQ:BLTE) Shares Gap UpHere's Why - MarketBeat

Sep 13, 2025

Sep 12, 2025

Using RSI to spot recovery in Belite Bio Inc Depositary ReceiptJuly 2025 Patterns & Consistent Profit Alerts - Newser

Sep 12, 2025

Sep 12, 2025

Will earnings trigger a reversal in Belite Bio Inc Depositary ReceiptEarnings Growth Summary & Low Drawdown Investment Ideas - Newser

Sep 12, 2025

Sep 12, 2025

Belite Bio completes last subject visit in phase 3 Stargardt trial - Investing.com

Sep 12, 2025

Sep 12, 2025

First-Ever Phase 3 Trial for Stargardt Disease: Belite Bio's Tinlarebant Could Be Breakthrough Treatment - Stock Titan

Sep 12, 2025

Sep 11, 2025

How to build a dashboard for Belite Bio Inc Depositary Receipt stock2025 Price Targets & Community Consensus Picks - Newser

Sep 11, 2025

Sep 11, 2025

Alyeska Investment Group L.P. Makes New Investment in Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat

Sep 11, 2025

Sep 11, 2025

Belite Bio, Inc. ADR (BLTE) Gets a Buy from Benchmark Co. - The Globe and Mail

Sep 11, 2025

Sep 11, 2025

Belite Bio Secures $125 Million in PIPE Financing with Potential for More - MSN

Sep 11, 2025

Sep 10, 2025

Benchmark reiterates Buy rating on Belite Bio stock after $275 million PIPE - Investing.com

Sep 10, 2025

Sep 10, 2025

Resilient Performance and Strategic Growth Drive Buy Rating for Harvard Bioscience Amid Market Challenges - TipRanks

Sep 10, 2025

Sep 08, 2025

Belite Bio raises $125 million in private placement for eye disease drugs By Investing.com - Investing.com South Africa

Sep 08, 2025

Sep 08, 2025

Belite Bio raises $125 million in private placement for eye disease drugs - Investing.com

Sep 08, 2025

Sep 08, 2025

$275M Biotech Deal: Belite Bio Lands Major Financing for Eye Disease Treatments from Top Healthcare Funds - Stock Titan

Sep 08, 2025

Sep 06, 2025

Belite Bio (NASDAQ:BLTE) Stock Price Down 2.3%Here's Why - MarketBeat

Sep 06, 2025

Sep 02, 2025

Belite Bio (NASDAQ:BLTE) Shares Down 2.3% – Here’s What Happened - Defense World

Sep 02, 2025

Sep 01, 2025

Can Belite Bio Inc Depositary Receipt maintain its current growth rateMarket Movers & Safe Entry Point Identification - خودرو بانک

Sep 01, 2025

Aug 31, 2025

Developing predictive dashboards with Belite Bio Inc Depositary Receipt data2025 Big Picture & Long-Term Growth Stock Strategies - Newser

Aug 31, 2025

Aug 29, 2025

Does Belite Bio Inc Depositary Receipt fit your quant trading model2025 Technical Patterns & Long-Term Safe Investment Plans - Newser

Aug 29, 2025

Aug 28, 2025

Belite Bio’s Earnings Call: Progress Amid Challenges - MSN

Aug 28, 2025

Aug 28, 2025

Is Belite Bio Inc Depositary Receipt showing signs of accumulationQuarterly Earnings Report & Entry and Exit Point Strategies - Newser

Aug 28, 2025

Aug 27, 2025

Clinical-Stage Biotech Belite Bio Secures Speaking Slots at Three Premier Healthcare Conferences - Stock Titan

Aug 27, 2025

Aug 26, 2025

Multi factor analysis applied to Belite Bio Inc Depositary ReceiptQuarterly Performance Summary & AI Driven Price Forecasts - Newser

Aug 26, 2025

Aug 26, 2025

Is Belite Bio Inc Depositary Receipt stock bottoming out2025 Price Momentum & Fast Exit Strategy with Risk Control - Newser

Aug 26, 2025